Colivac

DESCRIPTION

The general objective of the project was the development of an effective vaccine that slows down the expansion of emerging multiresistant antibiotic clones, which occur among extraintestinal pathogenic E. coli strains (ExPEC strains) that cause recurrent cystitis. This vaccine should protect not only systemically (against severe sepsis), but also at the level of the urinary mucosa, preventing adhesion and bacterial colonization (first step of the infective process of ExPEC).

The specific objective of NANOGAP was to study the biological activity of M-M and its use alone or as a co-adjuvant in the administration of antigenic proteins from the E. Coli bacteria.

The project was successfully completed after concluding all of the tasks, achieving the expected objectives. Although not all the prototypes could be validated due to not having a pilot plant, two vaccines were developed with positive results in terms of evidence of efficacy. NANOGAP successfully completed the production tasks, scaling, characterization and post-processing of M-M, being able to advance its action as vaccine adjuvant.

Funding info

this project has received funding from the FEDER INNTERCONECTA 2011 call, co-financed by the European Union through FEDER funds, under grant agreement ITC20113038.

Consortium members

• BIOFABRI
• CZ VETERINARIA
• NANOIMMUNOTECH
• NANOGAP
• USC
• Uvigo